GAPDHP62

Across TCGA pan-cancer cohorts, GAPDHP62 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of GAPDHP62’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GAPDHP62 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GAPDHP62 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

KIRC, HNSC, and COAD are the cancer types where GAPDHP62 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GAPDHP62 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.105	<.001	11	view →
HNSC	Male	II,III,IV	+0.262	<.001	10	view →
COAD	Female	II,III,IV	+0.328	<.001	9	view →
LUAD	All	All	+0.272	<.001	9	view →
LUSC	Male	All	+0.478	<.001	8	view →
BLCA	All	III,IV	+0.276	<.001	8	view →
STAD	Male	All	+0.293	<.001	6	view →
UCEC	All	III,IV	+0.232	.012	6	view →
BRCA	All	II,III,IV	+0.228	<.001	6	view →
LIHC	Male	All	+0.118	<.001	6	view →
READ	All	III,IV	+0.524	.013	2	view →
CHOL	All	All	+0.416	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

GAPDHP62–KIRC

Open the KIRC breakdown →